Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 71

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 71
---
 all such agreements
have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation
or unauthorized disclosure of our trade secrets and intellectual property could impair our competitive position and may have a material
adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets and intellectual property are deemed inadequate,
we may have insufficient recourse against third parties for misappropriating the trade secret.

Intellectual property rights of third parties could adversely affect
our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from third parties in order
to develop or market our product candidate. Such litigation or licenses could be costly or not available on commercially reasonable terms.

It is inherently difficult to conclusively assess
our freedom to operate without infringing on third party rights. Our competitive position may suffer if patents issued to third parties
or other third-party intellectual property rights cover our product candidates or elements thereof, or our manufacturing or uses relevant
to our development plans. In such cases, we may not be in a position to develop or commercialize products or our product candidates unless
we successfully pursue litigation to nullify or invalidate the third party intellectual property right concerned, or enter into a license
agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending patent
applications that if they result in issued patents, could be alleged to be infringed by our product candidates. If such an infringement
claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our product candidates
or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms,
if at all.

It is also possible that we have failed to identify
relevant third-party patents or applications. For example, U. S. applications filed before November 29, 2000 and certain U. S. applications
filed after that date that will not be filed outside the U. S. remain confidential until patents issue. Patent applications in the U. S.
and elsewhere are typically published approximately 18 months after the earliest filing to which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform
technology could have been filed by others without our knowledge. Additionally, pending